In a real-world setting, IER was associated with a dramatically lower risk of PDDP, independent of its glucose-lowering effect. These findings position IER as a potent, scalable non-pharmacological strategy to improve patient-centered outcomes in diabetes care.
Xiao et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: